Last reviewed · How we verify
Benralizumab Arm B
Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduced airway inflammation.
Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduced airway inflammation. Used for Moderate-to-severe eosinophilic asthma, Severe asthma with eosinophilic phenotype.
At a glance
| Generic name | Benralizumab Arm B |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | IL-5 receptor antagonist monoclonal antibody |
| Target | IL-5RA (Interleukin-5 Receptor Alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Respiratory |
| Phase | Phase 3 |
Mechanism of action
Benralizumab targets the interleukin-5 (IL-5) receptor alpha subunit, which is expressed on eosinophils and basophils. By blocking this receptor, the drug prevents IL-5 signaling and induces antibody-dependent cell-mediated cytotoxicity (ADCC), resulting in rapid depletion of these immune cells. This mechanism reduces eosinophilic inflammation in the airways, making it effective for eosinophilic asthma and other eosinophil-driven conditions.
Approved indications
- Moderate-to-severe eosinophilic asthma
- Severe asthma with eosinophilic phenotype
Common side effects
- Headache
- Nasopharyngitis
- Upper respiratory tract infection
- Injection site reactions
Key clinical trials
- A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO) (PHASE2)
- BenRalizumab Effect on Airway Remodeling in Severe asTHma (PHASE4)
- A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist (PHASE3)
- A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA (PHASE3)
- Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (PHASE3)
- Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (PHASE3)
- Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy (PHASE3)
- Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Benralizumab Arm B CI brief — competitive landscape report
- Benralizumab Arm B updates RSS · CI watch RSS
- AstraZeneca portfolio CI